Urea cycle disorders are incurable enzymopathies that affect nitrogen metabolism and typically lead to hyperammonemia. Arginase deficiency results from a mutation in Arg1, the enzyme regulating the final step of ureagenesis and typically results in developmental disabilities, seizures, spastic diplegia, and sometimes death. Current medical treatments for urea cycle disorders are only marginally effective, and for proximal disorders, liver transplantation is effective but limited by graft availability. Advances in human induced pluripotent stem cell research has allowed for the genetic modification of stem cells for potential cellular replacement therapies. In this study, we demonstrate a universally-applicable CRISPR/Cas9-based strategy utilizing exon 1 of the hypoxanthine-guanine phosphoribosyltransferase locus to genetically modify and restore arginase activity, and thus ureagenesis, in genetically distinct patient-specific human induced pluripotent stem cells and hepatocytelike derivatives. Successful strategies restoring gene function in patient-specific human induced pluripotent stem cells may advance applications of genetically modified cell therapy to treat urea cycle and other inborn errors of metabolism.
Introduction
Urea cycle disorders (UCDs) are rare enzymopathies with an incidence of 1:35,000 births resulting in ~113 new cases per year in the United States. 1 They are a significant cause of inherited hyperammonemia and afflicted infants, while newborns are at substantial risk of recurrent brain injury and death. Excessive plasma ammonia is neurotoxic, resulting in central nervous system injury including intellectual disabili ties, seizures, and loss of psychomotor function [1] [2] [3] [4] [5] ; they also live with continued nitrogen vulnerability. UCDs result from a deficiency in one of six hepatic enzymes or two mitochondrial transporters that regulate nitrogen metabolism and urea pro duction [1] [2] [3] 5 which are typically classified as an inborn errors of metabolism.
Hyperargininemia, or arginase deficiency, is an autoso mal recessive disorder that affects the final step of the urea cycle. Patients who exhibit hyperargininemia typically pres ent, after the neonatal period, with spasticity, seizures, spas tic diplegia, and developmental regression, differing from the other UCDs. [5] [6] [7] [8] Arginase 1 (Arg1) is primarily located in the liver, hydrolyzing arginine to urea while regenerating orni thine to continue the cycle. 6, 8 Loss of Arg1 activity results in an inability to remove nitrogen from arginine, but rarely causes symptoms of hyperammonemia. Instead, the cause of the pathogenesis of neurological deterioration in arginase deficiency is not known and is thought to be due to unique biochemical abnormalities such as elevated guanidino com pounds, nitric oxide, or glutamine. 3, [8] [9] [10] As there is no completely effective treatment for UCDs, the mainstay of therapy is dietary protein restriction, with emergency treatments for hyperammonemia consisting of dialysis, hemofiltration, and administration of nitrogen scav enging drugs. 5 Chronic therapy is minimally effective in reducing plasma ammonia while control of hyperargininemia may delay the onset of symptoms 6, 8 but may not ultimately prevent the progressive and relentless nature of neurocogni tive decline. Liver transplantation is the extreme alternative to conventional therapies to prevent progression of neuro logical injury in UCD patients. However, the demand for liver donors far exceeds the supply, and other avenues, such as genetic modification and cell replacement therapy, need to be explored to treat these disorders.
Since the demonstration that human induced pluripotent stem cells (hiPSCs) could be reprogrammed from fibroblasts with four transcription factors (Oct4, Sox2, Klf4, and cMyc), hiPSCs have emerged as a potential avenue for patient specific disease modeling and development of therapy. [11] [12] [13] [14] [15] Whereas the difficulty in obtaining primary cell cultures previ ously hindered progress of disease research, the ability of patientspecific hiPSCs to differentiate into genetically similar somatic cell types of various lineages, such as hepatocytes, allows for the generation of a substantial quantity of patient specific cells. 16, 17 These hiPSCderived hepatocytes express liverspecific markers such as albumin (ALB), alphafetopro tein (AFP), and cytokeratin 18 (CK18) as well as functionality markers such α1antitrypsin (AAT) and CYP3A4, demon strating their phenotypic similarity to endogenously derived hepatocytes. 17 Reprogramming patientspecific hiPSCs and establishing isogenic and functional derivatives afford the advantage of avoiding the ethical controversy of oocyte derived embryonic stem cell use and potentially addressing the immunogenicity issues for cell replacement therapies. 18 In this study, we sought to correct the enzyme deficiency, using a universal approach, in multiple arginasedeficient hiPSC lines derived from hyperargininemic patients by using genome editing technology. We delivered clustered inter spaced short palindromic repeats (CRISPR)/Cas9 nickases via nucleofection for gene addition of a fulllength codonopti mized human arginase 1 cDNA (ArgO) expression cassette (Left homologous armhEF1aArgOIRESPuro(R)Right homologous arm (LEAPR)) into Exon 1 of the endogenous hypoxanthineguanine phosphoribosyltransferase (HPRT) locus in hiPSCs. 19 After targeted insertion and puromycin selection (enabled by the LEAPRderived puromycin Nacetyl transferase (PAC)), and with confirmation of the presence of the LEAPR cassette in the patientspecific hiPSCs, we dem onstrated the restoration of arginase activity in both hiPSCs and differentiated hepatocytelike cells. Results from this genetic targeting approach potentially offer a widely applicable method to genetically introduce arginase expression in hiP SCs derived from hyperargininemic patients and, on a broader scale, to other singleenzyme inborn errors of metabolism.
Results

Derivation of patient-specific hiPSCs from arginasedeficient dermal fibroblasts
We derived geneticallydistinct hiPSC lines from dermal fibroblasts taken from three patients with hyperargininemia. The first disease dermal fibroblast line, AD1, originating from a female argininemic patient, was purchased from Coriell (GM00954). Two additional dermal fibroblast lines, AD2 and AD3, were derived from skin punch biopsies obtained from a male and female patient, respectively. The AD dermal fibro blasts were successfully reprogrammed to hiPSCs using a lentiviral vector expressing a constitutive polycistronic cas sette (STEMCCA) encoding the four transcription factors OCT4, SOX2, KLF4, and cMyc. 11, 20, 21 Dermal fibroblasts were transduced with the STEMCCA lentivirus and were main tained in culture for 30 days on mouse embryonic fibroblasts before conversion to feederfree culture conditions. The con trol hiPSC line (xcHUF1), derived from the dermal fibroblasts of a healthy adult male was previously established in the lab using the same reprogramming methodology. 22 AD1, AD2, and AD3 hiPSC lines exhibited normal stem celllike morphology throughout the course of the study. Char acterization of the AD hiPSCs included immunophenotyping for common pluripotent stem cell markers, alkaline phos phatase staining, in vivo teratoma formation, and karyotype analysis. AD1, AD2, and AD3 hiPSCs stained positive for pluripotency markers: Oct4, NANOG, SSEA3, SSEA4, Tra 1-60, Tra1-81 and all exhibited positive alkaline phospha tase activity (Figure 1a) . Normal karyotypic analyses, with no genomic abnormalities, were detected through Gband ing studies of AD1, AD2, and AD3 hiPSC lines (Figure 1b) . Furthermore, AD hiPSCs were collected and injected subcu taneously into the hindleg of SCID mice for in vivo teratoma analysis. Teratoma sections from AD1, AD2, and AD3 were stained with H&E and exhibited formation of gut (endoderm), neuroectoderm (ectoderm), and chondrocyte (mesoderm) derivatives, demonstrating the ability of our hiPSCs to form tissues from all three germ layers (Figure 1c) . Additionally, the specific arginase mutations were determined for each line (Figure 1d) . Characterization of all three diseased hiP SCs was compared with nondiseased controls as xcHUF1 hiPSCs and demonstrated no difference in pluripotency pro file (data not shown).
Design of ArgO and vectors for gene correction of hiPSCs
To correct for the mutant Arg1 gene in our patientderived AD hiPSCs, we designed a selectable, fulllength codon optimized human arginase cDNA (ArgO) expression cas sette under the constitutive control of the human elongation factor 1α (hEF1α) promoter, referred to as LEAPR, to be inserted into Exon 1 of the HPRT locus (Figure 2a) . Utilizing CRISPR/Cas9 nickases to bind and cleave Exon 1 of HPRT, we achieved targeted LEAPR addition into this desired site. LEAPR addition and disruption of the HPRT locus allowed for secondary positive clonal selection of successful ontarget integration via resistance to 6thioguanine (6TG) treatment. Additionally, a puromycin resistance gene encoded within the LEAPR construct afforded the ability to utilize an efficient dual selection method to isolate a clonal population of cells that successfully integrated our vector into the HPRT locus. After dual selection with puromycin and 6TG, AD1, AD2, and AD3 hiPSCs maintained normal stem celllike morphology (data not shown).
Evaluation of targeted integration and expression of ArgO into corrected hiPSCs
After delivery of the LEAPR construct, we performed experi ments to verify correct ontarget integration into the AD hiP SCs. AD hiPSCs were first dualselected by two cycles of 1 μg/ml puromycin treatment for 72 hours followed by 6TG treatment. Dualresistant cell populations were then clonally selected into three subclones each for all AD hiPSC lines. To analyze the targeted integration of our donor vector into Exon 1 of the HPRT locus, primers were designed to span each junction between the endogenous genome and our inserted vector. For each junction, one primer was designed to bind a region of the genome outside of the homologous arm region, and another was designed to bind a sequence within our inserted donor vector. Products at both 5′ and 3′ junction sites demonstrated ontarget integration of our LEAPR construct in each of three subclones of the corrected AD1, AD2, and AD3 hiPSC lines (Figure 2b (for AD1) and Supplementary Figure S1 (for AD2 and AD3)). Additionally, sequencing analysis of the junction PCR products showed the seamless transition between donor vector sequence and the endogenous genome sequence of our genecorrected cell lines at both the 5′ and 3′ junctions of our gene cassette insert (Figure 2c (for AD1) and Supplementary Figure S1 (for AD2 and AD3)).
To further characterize the targeted integration of LEAPR into the AD hiPSCs, we utilized quantitative reverse tran scriptionpolymerase chain reaction (qRTPCR) to deter mine whether the LEAPR construct integrated into one or both HPRT alleles in corrected AD1 and AD3 LEAPR hiP SCs and also used sequencing technology to further exam ine AD1. As AD1 and AD3 are XX and AD2 is XY, qRTPCR confirmed and demonstrated twice the levels of genomic HPRT (gHPRT) in AD1 and AD3 compared with AD2 rela tive to genomic glyceraldehyde 3phosphate dehydrogenase (gGAPDH) (Supplementary Figure S2, top) . Furthermore, qRTPCR demonstrated equal amplification of ArgO, a unique element of the LEAPR construct, relative to gGAPDH dem onstrating an equal number of LEAPR integrations through out the genomes of AD LEAPR hiPSCs (Supplementary Figure S2, middle) . Finally, qRTPCR demonstrated AD1 and AD3 with half the level of ArgO compared with AD2, rela tive to HPRT consistent with the integration of 1 LEAPR copy per two HPRT alleles in AD1 and AD3 and one LEAPR copy per one HPRT allele in AD2 (Supplementary Figure S2 , bottom). We also sequenced the other HPRT allele of AD1 which showed lack of integration, confirming that only one allele had the integrated donor arginase construct. However, because of nuclease activity at that site, five genetic muta tions were introduced in the other HPRT allele, the first four being silent mutations and the fifth resulting in a serine to phenylalanine amino acid change (Figure 2d) .
Offtarget analysis was performed in AD1 LEAPR hiPSCs to determine and quantify potential insertions and deletions due to offtarget sequence homology for nickases A and B.
High probability sites for offtarget nickase binding for each nuclease were determined in silico (probability scores of 1.37, 0.86, and 0.86 for nickase A and 0.58 for nickase B (out of a maximum score of 100)) were examined via sequenc ing. Analysis demonstrated 0% insertions and deletions at all sites (Supplementary Figure S3a,b) .
Arginase levels were examined in the LEAPRcorrected hiPSC lines by measuring RNA expression via qRTPCR and functionality via urea production (i.e., restoring ureagenesis). After puromycin and 6TG selection, corrected hiPSCs (n = 3) expressed significantly higher RNA levels (P < 0.0001) of codon optimized arginase compared with wild type arginase RNA levels in uncorrected AD hiPSCs, demonstrating on target integration and expression in all three corrected hiPSC lines. The integration of ArgO increased arginase mRNA lev els in AD1, AD2, and AD3 hiPSCs to 57, 92, and 46% (repli cates of n = 3 per sample) respectively when compared with wild type arginase levels in human fetal liver (Figure 3a Additionally, all corrected AD hiPSCs exhibited a significant increase (P < 0.0001) in urea production itself (i.e., functional activity) when compared with their uncorrected counterparts. Functionality of corrected AD1 hiPSCs increased to 102% (P = 0.0212) of that measured in human fetal liver lev els (Figure 3b for AD1). Varying degrees of recovery were observed in AD1, AD2, and AD3 corrected lines; however, the lowest recorded recovery level was still 71% of the primary fetal liver (Figure 3b and Supplementary Figure S5 for AD2 and AD3). Taken together, these data demonstrate (i) a high specificity of integration into Exon 1 of the HPRT target site as well as (ii) a high codon optimized arginase RNA expression with substantial functional arginase enzyme activity in hiPSCs.
Directed differentiation of human pluripotent cells into hepatocyte-like cells
Using a previously published protocol, 17 we differentiated the corrected AD1, AD2, and AD3 hiPSCs, their uncorrected 
Evaluation of arginase expression and functionality in hepatocyte-like cells
We examined codon optimized arginase RNA expression and functionality in the hiPSCderived hepatocytelike cells to determine the maintenance of arginase expression after directed differentiation. After the final differentiation step, RNA was collected from LEAPRcorrected AD1, AD2, and AD3 hepatocytelike cells; arginase levels were quantified and compared with both corrected hiPSC and fetal liver levels via qRTPCR. Hepatic differentiation did result in a decrease in arginase RNA expression in all three LEAPRcorrected hepatocytelike cell lines compared with undifferentiated hiPSCs (P < 0.0001 for AD1; P < 0.0002 for AD2 and AD3) (Figure 4c left panel for AD1 and Supplementary Figure S5 for AD2 and AD3 respectively). However, despite the decline in RNA expression compared with hiPSCs, AD1, AD2, and AD3 hepatocytelike cells maintained arginase levels of 27, 39, and 36% of fetal liver Arg1 levels (AD1, AD2, and AD3 respectively).
Next, we determined if targeted integration of the LEAPR construct affected expression of the wild type mutated argi nase and other endogenous urea cyclespecific genes in the hepatocytelike cells, specifically, carbamoyl phosphate syn thase 1 (CPS1), which catalyzes the synthesis of carbamoyl phosphate from glutamine. We measured mRNA levels of CPS1 in both uncorrected and corrected hiPSCs and hepa tocytelike cells (Supplementary Figure S7) . Similar to wild type mutated arginase mRNA expression, CPS1 levels were significantly increased postdifferentiation in both uncorrected and corrected lines (P = 0.01 for AD1 uncorrected lines; P < 0.0001 for AD1 corrected, AD2 uncorrected and cor rected, and AD3 uncorrected and corrected lines). These data suggest that the increasing arginase expression with our LEAPR construct in the disease lines does not negatively impact the expression of other endogenous urea cyclespe cific genes.
With the described decline in RNA expression, there was an expected postdifferentiation decline observed in ureagen esis of the LEAPR derivatives (P = 0.0004 for AD1; P < 0.001 for AD2; P < 0.0007 for AD3 compared with corrected hiP SCs). Importantly, though, all three corrected hepatocytelike cell lines maintained >40% of the level of urea production (i.e., arginase activity) of fetal liver (Figure 4c , right panel for AD1 and Supplementary Figure S5 for AD2 and AD3 respectively).
Discussion
Chronic therapy for UCDs includes dietary restriction to limit nitrogen intake and pharmacological intervention with nitro gen scavenging drugs (e.g., phenylbutyrate). Such substrate restriction is commonly used for treating UCDs while it is somewhat effective, this is more prophylactic than curative and patients remain at risk for developing longterm neuro logical issues due to intermittent hyperammonemia. Gene and stem cell therapy have emerged as promising therapeu tic avenues to treat these disorders and prevent the develop ment of hyperammonemiainduced neurological injury. [24] [25] [26] [27] [28] Stem cells, specifically hiPSCs, provide an almost inex haustible source of patientspecific cells that can undergo directed differentiation into various somatic cell types to be used for cellular replacement therapies. [29] [30] [31] Due to their ther apeutic potential, considerable effort has been aimed into optimizing protocols to genetically modify these cells in order to model diseases and to use in potential cellular therapies. 32 However, despite the promise of utilizing genetically modified hiPSCs for therapeutic studies, the ability to efficiently deliver genes to targeted sites in hiPSCs is hampered by several challenges. Nonviral methods, such as chemical transfec tion or electroporation, and viral methods, via lentiviruses or adenoassociated viruses, all suffer from relatively low transfection and transduction efficiencies, transient expres sion, and offtarget integration in the host hiPSC genome. 25, 32 Recently, the development of highly specific CRISPRs and CRISPRassociated (Cas) systems to introduce genes into hiPSCs have begun to address many previous issues sur rounding genomic editing of stem cells. Unlike its prede cessors, such as zinc finger nucleases and transcription activatorlike effector nucleases, CRISPR/Cas9 systems can be produced rapidly and introduced into specific target sites with increased accuracy. 19, 33, 34 As such, recent studies have demonstrated highly efficient genetic correction of hiPSCs utilizing CRISPR/Cas9 for neural and muscular disorders. 35 The goal of this study was to determine if integration of codonoptimized arginase into three genetically distinct patientspecific hiPSCs could produce in vitro enzyme func tion after differentiation into hepatocytelike derivatives for potential use in cellular therapy for these patients. Previous gene therapy studies have demonstrated successful reversal of disease manifestations through either treatment of neona tal mice with a helperdependent adenoviral vector 24 or with adenoassociated virusexpressing arginase. 36 In the former, the transient nature of expression led to loss of arginase function while in the later, longterm survival without neuro pathology was achieved; however, with the loss of episomal adenoassociated virus genomes, the level of arginase expression was low and therefore, the animals remained nitrogen vulnerable. 7 However, these murine studies were able to determine that longterm survival 36 with normal behavior and learning 37 was possible and that only low levels of hepatic arginase activity, as low as 3.5-5%, were neces sary to prevent brain injury and/or death from hyperammo nemia or hyperargininemia. 7 Here, we developed a CRISPR/ Cas9based strategy to deliver a codonoptimized version of human arginase 1 into hiPSCs derived from patients with arginase deficiency. Arg1 was introduced into Exon 1 of the HPRT locus via a construct containing right and left homolo gous arms, the human elongation factor 1α promoter, a poly adenylation signal, and puromycin for selection (LEAPR), resulting in substantial arginase enzymatic activity in hiPSCs and in differentiated derivatives.
Cellular HPRT is an enzyme that catalyzes the conversion of hypoxanthine to inosine monophosphate and guanine to guanosine monophosphate in the nonessential purine sal vage pathway. 38 Homozygous loss of HPRT function results in LeschNyhan syndrome, which causes an overproduction of uric acid. However, in normal conditions, purine salvage and HPRT do not play a major role in cell growth and prolif eration 39 ; in therapeutic administration of cells where HPRT is not functional in the large mass of HPRTpositive cells (such as the liver), it is believed that this loss will be incon sequential in purine metabolism. There are certainly desir able selective advantages of utilizing HPRT for integrated cell selection: HPRTpositive cells are sensitive to 6thiogua nine (6TG), killing cells by postreplicative mismatch repair 40 ; additionally, this mechanism allows for secondary selection with 6TG after HPRT locus disruption. 41, 42 As transfection efficiency of hiPSCs is inherently low, the incorporation of a dual selection method with puromycin and 6TG allowed us to purify a population of hiPSCs that contained the integrated construct at the targeted site utilizing nucleofection to deliver CRISPR/Cas9 nickases and the LEAPR cassette. In culture, these corrected hiPSCs showed that they maintained proper morphology and pluripotency, and sequencing data and qRT PCRbased genomic integration quantification confirmed that the constructs integrated into the correct targeted site in a single HPRT allele with no offtarget insertions and deletions at high unrelated probable sites. While the data demonstrate that a single X chromosome of each AD line is integrated with the donor construct, we did detect genetic mutations in the other allele of HPRT at the site of nuclease A and B activity.
Importantly, arginase was highly expressed in LEAPR corrected cells as shown by both qRTPCR and in urea production from functional arginase activity. After directed differentiation of LEAPRcorrected hiPSCs to the hepatic lin eage, the hepatocytelike cells were positive for albumin and αfetoprotein, stored glycogen, and expressed multiple liver specific RNAs. To determine if differentiation affected expres sion and functionality of arginase in the hepatocytelike cells, we quantified RNA levels and urea production for comparison with their hiPSC counterparts. While RNA levels of LEAPR derived arginase in hepatocytelike cells were lower when compared with their hiPSC counterparts, functional arginase expression with urea production for all LEAPRcorrected hepatocytelike cells remained, and at levels that were previ ously determined (with adenoassociated virusbased gene therapy) to be necessary for arginasedeficient mice to sur vive and be without neurodevelopmental abnormalities. As previous studies by others have shown a decline in transgene expression during differentiation with the use of the hEF1α promoter in embryonic stem cells, 43 this in part may explain the decline in expression in the hepatocyte derivatives in this study. Additionally, comparison of wild type mutated arginase and CPS1, another urea cycle enzyme, demonstrated that LEAPR modification does not negatively affect the expres sion of endogenous promoters of urea cycle enzymes. In aggregate, however, these data demonstrate that genetic modification at the HPRT locus of the arginasedeficient lines had no deleterious effect on their pluripotent capability and overall "stemness"; were not altered by nucleofection, selec tion, or culture of the hiPSCs; and were able to be differenti ated into hepatocytes with restoration of arginase activity and ureagenesis.
Based on these data, integration of Arg1 via the LEAPR expression construct by targeting the HPRT locus demon strates the potential for restoring enzymatic activity in cells derived from hyperargininemic patients. Previously, we have shown in a murine model that with relatively low overall hepatic arginase activity establishing ureagenesis at 3.5-5% of normal led to longterm survival with controlled plasma argi nine and ammonia; however these animals remained nitro gen vulnerable due to the low level of arginase expression. 7 LEAPRcorrected hepatocytelike cells across all three lines demonstrated functionality of at least 40% compared with fetal liver; while the hEF1α promoterbased expression did decline with cellular differentiation, arginase expression in our studies remains well above the minimum threshold needed for survival and adequate nitrogen metabolism determined from the prior murine arginase studies. 7 While our present LEAPR construct contains a copy of the selection marker puromy cin, an aminonucleoside antibiotic, before clinical applicabil ity alteration of our donor construct to avoid integration of an antimicrobial resistance gene and its potential immunogenic ity would be required. This would be accomplished by altering our donor construct by adding flanking loxP sites to the puro mycin cDNA such that it could excised at the hiPSC stage prior to differentiation to the hepatocyte lineage.
Over the last 30 years, multiple studies in rodents have shown that adult hepatocyte transplantation can reverse liver failure and can correct various metabolic deficiencies of the liver. 44, 45 While clinical trials of hepatocyte transplantation have demonstrated the longterm safety of cellular admin istration, only partial correction of metabolic disorders in humans has ever been achieved. 46, 47 In part due to the lim ited availability of fresh donor hepatocytes of adequate qual ity, clinical trials, however, have been hampered and reports have been limited in general to case reports involving a few patients at most and generally with no untreated controls. [48] [49] [50] [51] While attaining adequate engraftment will need further atten tion to make such therapies successful for patients with metabolic liver disorders, issues of cellular rejection should be greatly reduced 45 with an hiPSC approach as described herein.
In choosing this approach where cell availability and num bers of hepatocytes will not be a limitation, there are other important implications for treating more common monogenic disorders of the liver. The safe harbor of exon 1 of HPRT could be used in that the efficiency of homologous recom bination has been demonstrated here as well as the exog enous gene expression at this locus based on the hEF1α promoter. Targeted therapy of other liverbased disorders would be easily addressed by substitution of the arginase cDNA from the donor construct with one of the other enzyme cDNA sequences from another metabolic disorder.
This study presents an approach that can be utilized to integrate an optimized cassette into a universal site dis tant from protooncogenes in patientspecific hiPSCs to restore function of abnormal liver enzymes. While we have addressed the restoration and maintenance of transgene expression pre and postdifferentiation, additional studies are required to investigate the in vivo therapeutic efficacy of the corrected derivatives to maintain recovered arginase activity after cellular transplantation. Successful in vivo recovery of enzyme function by means of these strategies could benefit enzyme deficiencies of the urea cycle and other inborn errors of metabolism.
Materials and methods
In vitro derivation and culture of primary human dermal cells. The control human dermal fibroblast cell line (xc HUF1), obtained from UCLA Good Manufacturing Practice (GMP) facility, 22 and two disease fibroblast lines (AD2 and AD3) used in this study were obtained from adult skin punch biopsy (after IRB approval and informed consent) and were cultured in methods previously published. 11, 20 One adult dis ease fibroblast line (GM00954, renamed AD1) was obtained from Coriell Institute for Medical Research (Camden, NJ). All procedures were approved by the Institutional Review Board (IRB #13001469AM00002) and the Embryonic Stem Cell Research Oversight (ESCRO) (ESCRO #201001004A) Committee of the University of California, Los Angeles and informed consent was documented from both patients.
All fibroblast lines were cultured in media consisting of Dulbecco's modified Eagle medium nutrient mixture/F12 (DMEM/F12) (Invitrogen, Grand Island, NY), 10% fetal bovine serum (FBS) (Invitrogen), 1× Glutamax (Invitrogen), 1× minimum essential medium nonessential amino acid (Invi trogen) and 1× Primocin (InvivoGen, San Diego, CA). Cells were maintained in a 37°C 5% CO 2 incubator. Media was changed every 1-2 days and cells were passaged with 0.05% trypsinethylenediamine tetraacetic acid (EDTA) (Gemini Bio Products, West Sacramento, CA).
In vitro derivation and culture of human stem cell lines. The control hiPSC line xcHUF1 and the three disease hiPSC lines (AD1, AD2, and AD3) were developed by reprogramming from corresponding parental fibroblast lines via a lentiviral transduction of a stem cell cassette (STEMCCA) containing the reprogramming factors Oct4, Sox2, Klf4, and cMyc. 52 Fibroblasts were seeded at a confluency of 10,000 cells/ cm 2 prior to transfection. After viral transduction, cells were maintained in a 37°C 5% CO 2 incubator for 3 days in a defined media consisting of DMEM/F12 (Invitrogen) supplemented with 20% Knockout Serum Replacement (Invitrogen), 1× Glu tamax (Invitrogen), 1× Minimal Essential Media NonEssential Amino Acids Solution (Invitrogen), 1× Primocin (InvivoGen), 1× βmercaptoethanol (Millipore, Billerica, MA), and 10 μg/ml basic fibroblast growth factor (bFGF) (Biopioneer, San Diego, CA). After 3 days, the cells were passaged with 0.05% trypsin EDTA (Gemini BioProducts) onto a layer of mouse embryonic fibroblasts (GlobalStem, Rockville, MD) and maintained in cul ture up to 30 days until putative hiPSC colonies began to form. All cells were transitioned to and subsequently maintained in feederfree culture conditions consisting of reduced growth factor Matrigel (BD Biosciences, San Jose, CA) and a 50:50 mix of mTeSR1 media (StemCell Technologies, Vancouver, BC, Canada) and Nutristem (Stemgent, San Diego, CA) supplemented with 1× Primocin (InvivoGen) and 10 μg/ml bFGF. Cells were mechanically passaged every 4 to 5 days, depending on confluency and colony size. To passage the cells, pulled glass pipettes were used to crosshatch the colonies and to lift the pieces gently for transfer onto new Matrigelcoated plates.
DNA delivery by nucleofection. Cells were prepared for nucleofection by aspirating the media from each well and replacing with 2 ml of mTeSR/Nutristem media supplemented with 10 μmol/l ROCK inhibitor (BioPioneer, San Diego, CA). After 1 hour, the media was again aspirated and replaced with 1 ml Stempro Accutase (Life Technologies, Carls bad, CA) and incubated at 37ºC for 4-6 minutes in 1-2 ml of mTeSR1/Nutristem media supplemented with 10 μmol/l ROCK inhibitor in each well to neutralize the Accutase. Cells were then washed and gently scraped into suspension. The cell suspension was transferred to a sterile 15 ml conical tube and centrifuged for 5 minutes at 80g. The supernatant was aspirated and the cells were resuspended in an appropriate volume of mTeSR1/Nutristem media with ROCK inhibitor. 10 μl of the resuspended sample was removed and counted by hemocytometer. Samples planned for nucleofection were prepared as 800,000-1 million cells each. Aliquots were cen trifuged for 5 minutes at 80g. Supernatant were aspirated and the cells were resuspended in 100 μl of nucleofection solution (Lonza, Walkersville, MD) and placed into nucleofec tion cuvettes. (Care was taken to carefully resuspend cells to maximize the amount of single cells in suspension and to minimize cell death due to excessive mechanical stress). 1-2 μg of each DNA vector was added and mixed into the nucleofection solution. Controls, 1-2 μg of pMAXGFP, which is included in the kit, were added to one aliquot of each cell solution. The samples were then securely placed into an Amaxa Nucleofector II (Lonza) and nucleofected using the B016 program to facilitate cellular DNA vector uptake. The cells were then pipetted into either previously prepared Matrigelcoated plates or directly onto previously prepared plates of mouse embryonic fibroblasts. 72 hours after plating, mTeSR1/Nutristem media was supplemented with 1 μg/ml of puromycin for an additional 72 hours. Following puromycin selection, cells were cultured in mTeSR1/Nutristem media without puromycin. Colonies were expanded until large enough to isolate by mechanical passaging.
Hepatocyte differentiation of iPSCs. To begin hepatocyte dif ferentiation, hiPSCs were passaged at 90% confluency. The next day, the differentiation protocol began as previously published. 17 Briefly, hiPSCs were incubated for 24 hours with Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies, Carlsbad, CA), and supplemented with 0.5 mg/ ml bovine serum albumin (BSA; SigmaAldrich, St. Louis, MO), 100 ng/ml Recombinant Human Activin A (Peprotech, Rocky Hill, NJ), and 1× Primocin (Invivogen). On days 2 and 3, 0.1% and 1% insulintransferrinselenium (Life Technolo gies) were added to the previous supplemented RPMI 1640 medium, respectively. On day 4, hiPSCs were cultured with Hepatocyte Culture Medium (HCM) (consisting of HBM Basal Medium and HCM SingleQuot Kit) (Lonza) supplemented with 30 ng/ml Recombinant Human Fibroblast Growth Fac tor4 (FGF4) (Peprotech), 20 ng/ml Bone Morphogenetic Protein2 (BMP2) (Peprotech), and 1× Primocin (Invivo gen) for 4 days. The differentiated cells were then cultured in HCM containing 20 ng/ml Recombinant Human Hepatocyte Growth Factor (HGF), 20 ng/ml Recombinant Human Kera tinocyte Growth Factor (KGF), and 1× Primocin (Invivogen) for 6 days, and then in HCM supplemented with 10 ng/ml Recombinant Human Oncostatin M (OSM) (R&D Systems, Minneapolis, MN), 0.1 μmol/l dexamethasone (Sigma), and 1× Primocin (Invivogen) for the following 5 days. For the last 3 days of the hepatic differentiation, the cells were cultured in DMEM/F:12 (Life Technologies) supplemented with 1× N2, 1× B27, 1× GlutaMAX (Life Technologies), 1× NEAA (Life Technologies), 0.1 mmol/l βmercaptoethanol (Life Technolo gies), and 1× Primocin (Invivogen). All media and supple ments were filtered prior to use with a 0.22 micron filter and media was changed daily.
Immunocytochemistry. Cells were washed with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde (Polysciences, Warrington, PA) in 1× PBS for 15 minutes prior to staining. When necessary, samples were permea bilized in 1% Triton X100 (SigmaAldrich, St. Louis, MO) in PBS for 1 hour at room temperature. Subsequently, all samples were blocked with 5% goat serum (Sigma) in PBS for 1 hour at room temperature. Primary antibodies were diluted to working concentrations in 5% goat serum; cells were incubated with the primary antibody overnight in 4°C. After incubation, cells were washed three times with PBS at 5 minutes per wash. Secondary antibodies were diluted in 5% goat serum and cells were incubated for 1 hour at RT. Cells were washed three times with PBS and incubated with 1 × 4,6diamidino22phenylindole (DAPI; Thermo, Waltham, MA) for 7 minutes. Fluorescence images were captured with an Axiocam MR Monocolor Camera and AxioVision Digital Image Processing Software (Axio Observer Inverted Micro scope; Carl Zeiss, Jena, Germany). The primary and second ary antibodies used for hiPSC and hepatocytelike cells are listed in Table 1 .
Teratoma formation and analysis. Teratomas for the control and disease hiPSC lines were generated by injecting 1 × 10 6 cells (resuspended in Matrigel (BD Biosciences)) subcutane ously into both hind limbs of male severe combined immu nodeficient (SCID) mice (Charles River Laboratories, San Diego, CA). Tumors were harvested roughly 1-1.5 months after injection and fixed in 4% paraformaldehyde. Tissues were routinely processed and paraffinembedded followed by staining with hematoxylin and eosin (H&E). All animal experi ments adhered to policies set by the UCLA Animal Research Committee and the UCLA Division of Laboratory Animal Medicine (Protocol #200611922).
Karyotype analysis. The hiPSCs were cultured to 95-99% confluency in 25 cm 2 flasks and delivered to Cell Line Genet ics (Madison, WI) for Gband karyotyping analysis.
Reverse transcription PCR. RNA was extracted from primary fibroblasts, hiPSCs, and hepatocytelike cells with a Roche High Pure RNA Isolation Kit (Roche Applied Sciences, Indianapolis, IN) and 10 ng-1 μg was reversed transcribed to cDNA with the Transcriptor First Strand cDNA synthesis kit (Roche Applied Sciences) following the manufacturer's instructions. Primers were designed in NCBI/PrimerBlast and synthesized by Valugene (San Diego, CA) and are listed in Table 2 . RTPCR was performed with 25 ng of cDNA from each sample and each reaction was prepared with 12.5 μl 2× KAPA Fast Genotyping Mix (Kapa Biosystems, Wilmington, MA) and with 10 μmol/l forward and reverse primers and was run on a LightCycler 480 RealTime PCR System (Roche Applied Sciences). Gels were made with 2% agarose (Bio Rad Laboratories, Hercules, CA) and 1× SYBR Safe DNA Gel Stain (Life Technologies) in trisacetateEDTA (TAE) buf fer and run on a PowerPac Basic Power Supply (BioRad) at 90 V for 30 minutes. Human codon optimized arginase (ArgO) was developed by running the amino acid sequence of Arg1 through Gene Designer 2.0 software (DNA2.0, Menlo Park, CA) against the homo sapiens codon usage table. Once the initial sequence was produced, it was run through NetGene2 (http://www.cbs. dtu.dk/services/NetGene2/) to find any cryptic splice sites. This sequence was then checked for any long repeats in Oli gonucleotides Repeat Finder (http://wwwmgs.bionet.nsc.ru/ mgs/programs/oligorep/InpForm.htm). Any variations needed to delete splice sites or long repeats were silent mutations that used the next most common codon in the Homo sapiens codon usage table.
Junction PCR and sequencing analysis. To verify targeted integration of our donor vector in corrected hiPSCs, each 5′ and 3′ junction of the integrated vector was analyzed by PCR and DNA sequencing. Reactions were prepared with genomic DNA, 12.5 μl of Phusion HighFidelity PCR Master Mix (New England BioLabs, Ipwich, MA), 10.25 μl of water, and 1.25 μl of forward and reverse primers for the 3′ and 5′ ends of Exon 1 of HPRT ( Table 4) .
For sequencing, PCR bands were extracted and purified using the Wizard SV Gel and PCR Cleanup System (Pro mega, Madison WI) and the purified products were sent to Laragen (Culver City, CA) for sequencing analysis.
Off target analysis. To identify potential introduced muta tions at other regions in the genome, offtarget binding/cut ting of the DNA by the CRISPR/Cas9 nucleases resulting in insertions or deletions was analyzed at the predicted most common sites for each CRISPR/cas9 nickase as deter mined by the MIT CRISPR Design website (http://www. crispr.mit.edu). Each corresponding gDNA region sequence was downloaded from the PubMed genebank. PCR prim ers were designed using the ThermoFisher primer designer (http://www.thermofisher.com/oligoperfect.html). Appropriate primers were synthesized by Integrated DNA Technologies (Coralville, IA) to amplify each offtarget region. For par ticularly GCrich regions, 5% dimethylsulfoxide (DMSO) or Betaine (Sigma) was added. The region on the other HPRT allele was amplified using the same 5′F and 3′R junction PCR primers as was used for junction PCR analysis. Each potential offtarget region was amplified by PCR from both the parental and genetically modified gDNA samples of AD1 using the Phusion PCR Master Mix (ThermoFisher). PCR conditions were set according to manufacturer recommenda tions: (i) 98°C 30 seconds, (ii) 98°C 10 seconds, (iii) 57°C 30 seconds, (iv) 72°C 1 minute, Repeat 2-4 35×, (v) 72°C 5 minutes, and (vi) 4°C hold using Phusion highfidelity PCR master mix (ThermoFisher). PCR products were run on a 1% agarose gel for ~20 minutes at 100 V. Bands were extracted using the Wizard SV Gel and PCR Cleanup System, followed manufacturer protocol and were sequenced by Laragen.
To also determine if both HPRT alleles were integrated with the LEAPR construct, we performed quantitative real time PCR (ArgO, gGAPDH, and gHPRT) of each AD line know ing that AD1 and AD3 were XX and AD2 was XY ( Table 5) . Knowing this, we reasoned that we should see twice as much gHPRT in AD1 and AD3 compared with AD2 ( Supplementary  Figure S2, top) . In addition, we reasoned that we should see the same amount of ArgO expression in all three AD lines relative to GAPDH (Supplementary Figure S2, middle) . Finally, if only one allele was integrated we should detect half as much ArgO expression in AD1 and AD3 compared with AD2, relative to HPRT (i.e., 1 copy of ArgO per two copies of HPRT in AD1 and AD3 compared with 1 copy of ArgO per one copy of HPRT in AD2) (Supplementary Figure S2, bottom) .
Functional assay for arginase activity. Arginase activity was measured in cell lysates. 2 × 10 6 -4 × 10 6 cells were pelleted by lowspeed centrifugation and frozen for each sample. Cell pellets were lysed at 20,000 cells/μl in lysis buffer. Pri mary tissue sample controls were homogenized with 40 μl of lysis buffer/mg of tissue. Lysis buffer was prepared with 0.1% Triton X100 and 1× HALT protease inhibitor cocktail (Thermo) and urea production was measured as previously performed. 36, 54 Briefly, samples were centrifuged at 100g for 5 minutes at 4°C and the supernatant was collected. An acti vated mixture, consisting of 12.5 μl of 50 mmol/l TrisCl (pH 7.5), 12.5 μl of 10 mmol/l MnCl, and 25 μl of the supernatant was incubated at 56°C for 10 minutes. 2.5 μl of the activated mixture was added to 25 μl of 0.5 mol/l arginine (pH 9.7) and incubated at 37°C for 1 hour. After incubation, 72.5 μl ddH 2 O was added to bring the final volume to 100 μl. 400 μl of an acid mixture, consisting of one part H 2 SO 4 (95%), three parts H 3 PO 4 (85%), and seven parts ddH 2 O, in addition to 25 μl of 9% isonitrosopropiophenone (ISPF) in ethanol, was added to samples and urea standards. Urea standards were prepared at 9.3, 18.7, 37.5, 75, 150, and 300 μg/ml in ddH 2 O. The final mixture was incubated at 100°C for 45 minutes. After incu bation, samples were cooled to room temperature and pro tected from light for 10 minutes. 200 μl of each sample was aliquoted in duplicate and measured at an optical density of 540 nm in a 96well plate in a plate reader (BioRad).
Sequencing analysis. Fibroblasts were cultured in 25 cm 2 flasks and delivered to GeneDx (Gaithersberg, MD) for com plete Arg1 gene sequencing and mutation analysis. Mutations were analyzed in hiPSC and hepatocyte progeny in the UCLA Orphan Disease lab by PCR followed by Sanger sequencing. Select regions of the Arg1 gene were amplified by PCR using standard conditions (95° for 2 minutes (1 cycle)); 94° for 30 seconds, 60° for 30 seconds, 72° for 1 minute (35 cycles); 72° for 3 minutes (1 cycle); hold at 10°). Primer sequences for the c.61C>T variant were as follows: (5′TTTGCACAAACTACTTG TTCACTG3′; 5′TCAGAGTGGGGAGGAAATCA3′). Primers for the c.365G>A variant were as follows: (5′AAAACCAA GTGGGAGCATTG3′; 5′CCTTCCACCTCCTGAATGTC3′). Primers for the c.709G>A variant were as follows: (5′CATG AAATAATGGGTTGCTACTTTT3′; 5′TTGCTTCTCTATTACC TCAGATTGTT3′). Primers for the c.892G>C variant were as follows: (5′CCATCGGTTACTACCTTTTTCTG3′; 5′TCTG AAAGAACAAGTCTTTAGAAGG3′). An aliquot of each PCR product was confirmed by gel electrophoresis based on its predicted amplicon size. The rest of the PCR product was purified using the QIAquick PCR purification kit (Qiagen) and subjected to bidirectional sequencing using ABI BigDye v3.1 terminators on an ABI 3130xl genetic analyzer (Applied Biosystems, Foster City, CA). The sequence traces at each location were manually analyzed for the presence of a vari ant using the SequenceScanner v.1 software (Applied Bio systems) in comparison to the GenBank reference sequence NM_000045.3.
Statistical analysis. All collected data was analyzed with the SPSS (Armonk, NY) statistical package (Version 21.0). Results were expressed as mean ± standard deviation (SD) and Pvalues were determined using a oneway analysis of variance (ANOVA) to examine significance across compari sons. Error bars represent SD. Figure S1 . Integration of LEAPR cassette in AD2 and AD3 hiPSCs. 
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